Drug-eluting beads chemoembolization combined with programmed cell death 1 inhibitor and lenvatinib for large hepatocellular carcinoma

Table 5 Treatment-related adverse events in the two groups, n (%)

Adverse events	D-TACE-P-L (n = 50)		C-TACE-P-L (n = 54)		P value
	Any grade	Grade 3	Any grade	Grade 3
Diarrhea	9 (18.0)	2 (4.0)	7 (13.0)	1 (1.8)	0.717
Hand-foot syndrome	12 (24.0)	2 (4.0)	15 (27.8)	2 (3.7)	0.882
Hypertension	13 (26.0)	1 (2.0)	14 (26.0)	0 (0.0)	0.572
Fatigue	24 (48.0)	4 (8.0)	20 (37.0)	3 (5.6)	0.522
Anorexia and nausea	26 (52.0)	4 (8.0)	30 (55.6)	5 (9.3)	0.928
Rash	19 (38.0)	1 (2.0)	25 (46.3)	3 (5.6)	0.518
Thyroid dysfunction	6 (12.0)	0 (0.0)	10 (18.5)	1 (1.8)	0.485
Hyperbilirubinemia	11 (22.0)	2 (4.0)	9 (16.7)	1 (1.8)	0.738
Fever	46 (92.0)	6 (12.0)	48 (89.9)	3 (5.6)	0.462
Abdominal pain	34 (68.0)	6 (12.0)	33 (61.1)	2 (3.7)	0.336

C-TACE-P-L: Conventional transarterial chemoembolization combined with lenvatinib plus programmed cell death 1 inhibitor; D-TACE-P-L: Drug-eluting beads transarterial chemoembolization combined with lenvatinib plus programmed cell death 1 inhibitor.